3 Bio-Techs Insiders Love: Sequenom, Inc. (SQNM), Infinity Pharmaceuticals Inc. (INFI), MannKind Corporation (MNKD)

Pfizer’s product failed due to low absorption rates of its delivery mechanism. This low absorption resulted in lung deposits, which was a health risk. AFREZZA is a much safer product due to a better delivery mechanism and is also available at cheaper prices. These price levels will make it much easier for the company to compete with conventional insulin products.

The company is currently trading at a 35% discount to its mean sell side target price of $5.5. In the last six months insiders have purchased approximately 40 million shares of the company, increasing insider holdings by approximately 150%. In the same period institutions have increased their holdings by approximately 7 million shares, an increase of 17%.

All three companies provide a good buying opportunity for investors. Insider interest shows that good things can be expected from these stocks in the future. Prospective investors should do their own due diligence before going for anyone of these stocks.

The article 3 Bio-Techs Insiders Love originally appeared on Fool.com and is written by Mohsin Saeed.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.